{"symbol": "IBIO", "name": "iBio", "next_earnings_utc": 1592560800, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": null, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": null, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 0, "analysts_sell": null, "analysts_buy": null, "analysts_outperform": null, "analysts_hold": null, "analysts_underperform": null, "webpage": "ibioinc.com", "year_founded": null, "street_address": "600 Madison Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "302-355-0650", "short_description": "iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally.", "long_description": "iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 184641649, "total_enterprise": 208167649, "number_of_employees": 55, "outstanding_shares": 118360032, "eps": -0.974733, "diluted_eps": -0.974733, "earnings_from_cont_operations": -17408000, "gross_profit": 1313000, "cash": 10040000, "total_debt": 33575000, "total_revenue": 1313000, "cash_from_operations": -13870000, "net_income": -17404000, "ebitda": -12829000, "year_low_stock_price": 0.05, "year_high_stock_price": 3.4, "seekingalpha_follower_count": 11368, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/IBIO.png"}